The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

Nicholas J. Robert, Charles Vogel, I. Craig Henderson, Joseph A. Sparano, Melvin R. Moore, Paula Silverman, Beth A. Overmoyer, Charles L. Shapiro, John W. Park, Gail T. Colbern, Eric P. Winer, Alberto A. Gabizon

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active as any - and more active than most - drugs used to treat breast cancer. Their inclusion in combinations to treat early and advanced disease prolongs survival. However, they cause nausea, vomiting, alopecia, myelosuppression, mucositis, and cardiomyopathies. There is no evidence that increasing the dose of conventional anthracyclines or any other of the cytotoxics beyond standard doses will improve outcomes. Schedule may be more important than dose in determining the benefit of cytotoxics used to treat breast cancer. Weekly schedules and continuous infusions of 5-fluorouracil and doxorubicin may have some advantages over more intermittent schedules. Liposomal formations of doxorubicin reduce toxicity, including cardiotoxicity; theoretically they should also be more effective because of better targeting of tumor over normal tissues. Both pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) and liposomal doxorubicin (Myocet [NPLD]) appeared to be as effective as conventional doxorubicin and much less toxic in multiple phase II and phase III studies. PLD has been evaluated in combinations with cyclophosphamide, the taxanes, vinorelbine, gemcitabine, and trastuzumab, and NPLD has been evaluated in combination with cyclophosphamide and trastuzumab. Both liposomal anthracyclines are less cardiotoxic than conventional doxorubicin. The optimal dose of PLD is lower than that of conventional doxorubicin or NPLD. Patients treated with PLD have almost no alopecia, nausea, or vomiting, but its use is associated with stomatitis and hand-foot syndrome, which can be avoided or minimized with the use of proper dose-schedules. In contrast, the optimal dose-schedule of NPLD is nearly identical to that of conventional doxorubicin. The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses.

Original languageEnglish
Pages (from-to)106-146
Number of pages41
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 13
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Anthracyclines
Breast Neoplasms
Doxorubicin
Appointments and Schedules
gemcitabine
Therapeutics
Taxoids
Alopecia
liposomal doxorubicin
Cyclophosphamide
Nausea
Vomiting
Hand-Foot Syndrome
Pharmaceutical Preparations
Stomatitis
Mucositis
Poisons
Cardiomyopathies
Fluorouracil

ASJC Scopus subject areas

  • Oncology

Cite this

Robert, N. J., Vogel, C., Henderson, I. C., Sparano, J. A., Moore, M. R., Silverman, P., ... Gabizon, A. A. (2004). The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars in Oncology, 31(SUPPL. 13), 106-146. https://doi.org/10.1053/j.seminoncol.2004.09.018

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. / Robert, Nicholas J.; Vogel, Charles; Henderson, I. Craig; Sparano, Joseph A.; Moore, Melvin R.; Silverman, Paula; Overmoyer, Beth A.; Shapiro, Charles L.; Park, John W.; Colbern, Gail T.; Winer, Eric P.; Gabizon, Alberto A.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 13, 01.12.2004, p. 106-146.

Research output: Contribution to journalArticle

Robert, NJ, Vogel, C, Henderson, IC, Sparano, JA, Moore, MR, Silverman, P, Overmoyer, BA, Shapiro, CL, Park, JW, Colbern, GT, Winer, EP & Gabizon, AA 2004, 'The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer', Seminars in Oncology, vol. 31, no. SUPPL. 13, pp. 106-146. https://doi.org/10.1053/j.seminoncol.2004.09.018
Robert, Nicholas J. ; Vogel, Charles ; Henderson, I. Craig ; Sparano, Joseph A. ; Moore, Melvin R. ; Silverman, Paula ; Overmoyer, Beth A. ; Shapiro, Charles L. ; Park, John W. ; Colbern, Gail T. ; Winer, Eric P. ; Gabizon, Alberto A. / The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 13. pp. 106-146.
@article{9b3b1340bbc742638a337ebe0dfa1f3d,
title = "The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer",
abstract = "For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active as any - and more active than most - drugs used to treat breast cancer. Their inclusion in combinations to treat early and advanced disease prolongs survival. However, they cause nausea, vomiting, alopecia, myelosuppression, mucositis, and cardiomyopathies. There is no evidence that increasing the dose of conventional anthracyclines or any other of the cytotoxics beyond standard doses will improve outcomes. Schedule may be more important than dose in determining the benefit of cytotoxics used to treat breast cancer. Weekly schedules and continuous infusions of 5-fluorouracil and doxorubicin may have some advantages over more intermittent schedules. Liposomal formations of doxorubicin reduce toxicity, including cardiotoxicity; theoretically they should also be more effective because of better targeting of tumor over normal tissues. Both pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) and liposomal doxorubicin (Myocet [NPLD]) appeared to be as effective as conventional doxorubicin and much less toxic in multiple phase II and phase III studies. PLD has been evaluated in combinations with cyclophosphamide, the taxanes, vinorelbine, gemcitabine, and trastuzumab, and NPLD has been evaluated in combination with cyclophosphamide and trastuzumab. Both liposomal anthracyclines are less cardiotoxic than conventional doxorubicin. The optimal dose of PLD is lower than that of conventional doxorubicin or NPLD. Patients treated with PLD have almost no alopecia, nausea, or vomiting, but its use is associated with stomatitis and hand-foot syndrome, which can be avoided or minimized with the use of proper dose-schedules. In contrast, the optimal dose-schedule of NPLD is nearly identical to that of conventional doxorubicin. The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses.",
author = "Robert, {Nicholas J.} and Charles Vogel and Henderson, {I. Craig} and Sparano, {Joseph A.} and Moore, {Melvin R.} and Paula Silverman and Overmoyer, {Beth A.} and Shapiro, {Charles L.} and Park, {John W.} and Colbern, {Gail T.} and Winer, {Eric P.} and Gabizon, {Alberto A.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1053/j.seminoncol.2004.09.018",
language = "English",
volume = "31",
pages = "106--146",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 13",

}

TY - JOUR

T1 - The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

AU - Robert, Nicholas J.

AU - Vogel, Charles

AU - Henderson, I. Craig

AU - Sparano, Joseph A.

AU - Moore, Melvin R.

AU - Silverman, Paula

AU - Overmoyer, Beth A.

AU - Shapiro, Charles L.

AU - Park, John W.

AU - Colbern, Gail T.

AU - Winer, Eric P.

AU - Gabizon, Alberto A.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active as any - and more active than most - drugs used to treat breast cancer. Their inclusion in combinations to treat early and advanced disease prolongs survival. However, they cause nausea, vomiting, alopecia, myelosuppression, mucositis, and cardiomyopathies. There is no evidence that increasing the dose of conventional anthracyclines or any other of the cytotoxics beyond standard doses will improve outcomes. Schedule may be more important than dose in determining the benefit of cytotoxics used to treat breast cancer. Weekly schedules and continuous infusions of 5-fluorouracil and doxorubicin may have some advantages over more intermittent schedules. Liposomal formations of doxorubicin reduce toxicity, including cardiotoxicity; theoretically they should also be more effective because of better targeting of tumor over normal tissues. Both pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) and liposomal doxorubicin (Myocet [NPLD]) appeared to be as effective as conventional doxorubicin and much less toxic in multiple phase II and phase III studies. PLD has been evaluated in combinations with cyclophosphamide, the taxanes, vinorelbine, gemcitabine, and trastuzumab, and NPLD has been evaluated in combination with cyclophosphamide and trastuzumab. Both liposomal anthracyclines are less cardiotoxic than conventional doxorubicin. The optimal dose of PLD is lower than that of conventional doxorubicin or NPLD. Patients treated with PLD have almost no alopecia, nausea, or vomiting, but its use is associated with stomatitis and hand-foot syndrome, which can be avoided or minimized with the use of proper dose-schedules. In contrast, the optimal dose-schedule of NPLD is nearly identical to that of conventional doxorubicin. The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses.

AB - For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active as any - and more active than most - drugs used to treat breast cancer. Their inclusion in combinations to treat early and advanced disease prolongs survival. However, they cause nausea, vomiting, alopecia, myelosuppression, mucositis, and cardiomyopathies. There is no evidence that increasing the dose of conventional anthracyclines or any other of the cytotoxics beyond standard doses will improve outcomes. Schedule may be more important than dose in determining the benefit of cytotoxics used to treat breast cancer. Weekly schedules and continuous infusions of 5-fluorouracil and doxorubicin may have some advantages over more intermittent schedules. Liposomal formations of doxorubicin reduce toxicity, including cardiotoxicity; theoretically they should also be more effective because of better targeting of tumor over normal tissues. Both pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) and liposomal doxorubicin (Myocet [NPLD]) appeared to be as effective as conventional doxorubicin and much less toxic in multiple phase II and phase III studies. PLD has been evaluated in combinations with cyclophosphamide, the taxanes, vinorelbine, gemcitabine, and trastuzumab, and NPLD has been evaluated in combination with cyclophosphamide and trastuzumab. Both liposomal anthracyclines are less cardiotoxic than conventional doxorubicin. The optimal dose of PLD is lower than that of conventional doxorubicin or NPLD. Patients treated with PLD have almost no alopecia, nausea, or vomiting, but its use is associated with stomatitis and hand-foot syndrome, which can be avoided or minimized with the use of proper dose-schedules. In contrast, the optimal dose-schedule of NPLD is nearly identical to that of conventional doxorubicin. The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses.

UR - http://www.scopus.com/inward/record.url?scp=19944396126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944396126&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.09.018

DO - 10.1053/j.seminoncol.2004.09.018

M3 - Article

C2 - 15717740

AN - SCOPUS:19944396126

VL - 31

SP - 106

EP - 146

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 13

ER -